期刊
CANCERS
卷 14, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/cancers14092179
关键词
radiation-associated sarcoma; bone sarcoma; osteosarcoma; pelvis; sarcoma; surgical outcomes
类别
This study compared the surgical and oncologic outcomes of three types of sarcomas in the pelvis and sacrum. The results showed that patients with radiation-associated sarcomas had worse perioperative mortality rates and 5-year disease-specific survival rates compared to those with primary sarcomas.
Simple Summary Primary osteosarcomas, spindle cell sarcomas, and radiation-associated sarcomas arising in the pelvis and sacrum (RASB) represent challenging disease processes. The oncologic outcomes are similarly poor between these entities; however, the rates of perioperative death and 5-year disease specific survival for patients with RASB appear to be worse overall. While surgery can result in a favorable outcome for a small subset of patients, surgical treatment is fraught with complications. Radiation-associated sarcoma of the pelvis and/or sacrum (RASB) is a rare but challenging disease process associated with a poor prognosis. We hypothesized that patients with RASB would have worse surgical and oncologic outcomes than patients diagnosed with primary pelvic or sacral bone sarcomas. This was a retrospective, multi-institution, comparative analysis. We reviewed surgically treated patients from multiple tertiary care centers who were diagnosed with a localized RASB. We also identified a comparison group including all patients diagnosed with a primary localized pelvic or sacral osteosarcoma/spindle cell sarcoma of bone (POPS). There were 35 patients with localized RASB and 73 patients with POPS treated with surgical resection. Patients with RASB were older than those with POPS (57 years vs. 38 years, p < 0.001). Patients with RASB were less likely to receive chemotherapy (71% for RASB vs. 90% for POPS, p = 0.01). Seventeen percent of patients with RASB died in the perioperative period (within 90 days of surgery) as compared to 4% with POPS (p = 0.03). Five-year disease-specific survival (DSS) (31% vs. 54% p = 0.02) was worse for patients with RASB vs. POPS. There was no difference in 5-year local recurrence free survival (LRFS) or metastasis free survival (MFS). RASB and POPS present challenging disease processes with poor oncologic outcomes. Rates of perioperative mortality and 5-year DSS are worse for RASB when compared to POPS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据